Brokerage Firm Rating on GlaxoSmithKline PLC (GSK)

GlaxoSmithKline PLC (GSK) : 2 brokerage houses believe that GlaxoSmithKline PLC (GSK) is a Strong Buy at current levels. 3 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on GlaxoSmithKline PLC (GSK). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 5 Wall Street Analysts endorse the stock as a Buy with a rating of 2.2.

GlaxoSmithKline PLC (GSK) : The highest level GlaxoSmithKline PLC (GSK) is projected to reach is $50 for the short term and the lowest estimate is at $49. The consolidated price target from 2 rating analysts who initiate coverage on the stock is $49.5 and the possibility the share price can swing is $0.71.


For the current week, the company shares have a recommendation consensus of Buy. GlaxoSmithKline PLC (NYSE:GSK): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $44.25 and $44.15 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $44.41. The buying momentum continued till the end and the stock did not give up its gains. It closed at $44.39, notching a gain of 0.59% for the day. The total traded volume was 1,940,623 . The stock had closed at $44.13 on the previous day.

GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases. Its human immunodeficiency virus (HIV) business is managed through ViiV Healthcare. GSKs Vaccines has a portfolio of over 30 paediatric, adolescent, adult travel vaccines. GSKs Established Products Portfolio includes over 50 off-patent products, as well as its branded generics business and other local products. The Consumer Healthcare business develops and markets products in four categories, such as wellness, oral health, nutrition and skin health. Its brands include Sensodyne, Panadol, Horlicks, Polident, Paradontax, Tums, ENO, NiQuitin/Nicorette, Abreva, Zovirax and Aquafresh. It operates in the United Kingdom, the United States, Belgium and China.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.